ATE486892T1 - Verfahren zur kontrolle von krebs - Google Patents

Verfahren zur kontrolle von krebs

Info

Publication number
ATE486892T1
ATE486892T1 AT03794710T AT03794710T ATE486892T1 AT E486892 T1 ATE486892 T1 AT E486892T1 AT 03794710 T AT03794710 T AT 03794710T AT 03794710 T AT03794710 T AT 03794710T AT E486892 T1 ATE486892 T1 AT E486892T1
Authority
AT
Austria
Prior art keywords
cell
provides methods
ephb4
controlling cancer
cancerous growth
Prior art date
Application number
AT03794710T
Other languages
English (en)
Inventor
Sally-Anne Stephenson
Original Assignee
Queen Elizabeth Hospital Res F
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Queen Elizabeth Hospital Res F filed Critical Queen Elizabeth Hospital Res F
Application granted granted Critical
Publication of ATE486892T1 publication Critical patent/ATE486892T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT03794710T 2002-09-16 2003-09-16 Verfahren zur kontrolle von krebs ATE486892T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2002951409A AU2002951409A0 (en) 2002-09-16 2002-09-16 Methods for regulating cancer
PCT/AU2003/001209 WO2004024773A1 (en) 2002-09-16 2003-09-16 Methods for regulating cancer

Publications (1)

Publication Number Publication Date
ATE486892T1 true ATE486892T1 (de) 2010-11-15

Family

ID=27792678

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03794710T ATE486892T1 (de) 2002-09-16 2003-09-16 Verfahren zur kontrolle von krebs

Country Status (15)

Country Link
US (1) US7722866B2 (de)
EP (1) EP1546205B1 (de)
JP (1) JP4799863B2 (de)
KR (1) KR20050072744A (de)
CN (1) CN1694902B (de)
AT (1) ATE486892T1 (de)
AU (1) AU2002951409A0 (de)
BR (1) BR0314369A (de)
CA (1) CA2499130A1 (de)
DE (1) DE60334820D1 (de)
ES (1) ES2355503T3 (de)
MX (1) MXPA05002894A (de)
NZ (1) NZ539203A (de)
WO (1) WO2004024773A1 (de)
ZA (1) ZA200502863B (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6887674B1 (en) 1998-04-13 2005-05-03 California Institute Of Technology Artery- and vein-specific proteins and uses therefor
EP1606305A4 (de) 2003-03-12 2009-06-24 Vasgene Therapeutics Inc Nukleinsäureverbindungen für die inhibierung von angiogenese und tumorwachstum
US7381410B2 (en) 2003-03-12 2008-06-03 Vasgene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth
DE602005025459D1 (de) * 2004-03-12 2011-02-03 Vasgene Therapeutics Inc Ephb4-bindende antikörper zur inhibierung von angiogenese und tumorwachstum
EP2275445A3 (de) * 2004-03-12 2012-02-29 Vasgene Therapeutics, Inc. Ephb4-bindende Antikörper zur Inhibierung von Angiogenese und Tumorwachstum
CA2581423A1 (en) 2004-09-23 2006-03-30 Vasgene Therapeutics, Inc. Polipeptide compounds for inhibiting angiogenesis and tumor growth
EP1799867A2 (de) * 2004-09-23 2007-06-27 Vasgene Therapeutics, Inc. Zusammensetzungen und verfahren zur erkennung und behandlung von tumoren
AU2013200383B2 (en) * 2006-01-05 2016-05-12 Genentech,Inc. Anti-EphB4 antibodies and methods using same
TWI391402B (zh) * 2006-01-05 2013-04-01 Genentech Inc 抗ｅｐｈｂ４抗體及使用該抗體之方法
CN101395183B (zh) * 2006-01-05 2013-08-07 健泰科生物技术公司 抗ephb4抗体及其使用方法
EP1973950B1 (de) 2006-01-05 2014-09-17 Genentech, Inc. Anti-ephb4-antikörper sowie verfahren zu deren verwendung
CN101626784B (zh) * 2006-08-31 2013-07-17 作为康可信托公司受托人的A.C.N.135493391股份有限公司 利用包含抗体的组合物治疗和/或预防非传染性医学病症
WO2008104803A2 (en) * 2007-02-26 2008-09-04 Oxford Genome Sciences (Uk) Limited Proteins
EP2137216A2 (de) * 2007-03-12 2009-12-30 Vasgene Therapeutics, Inc. Verwendung von ephb4 als diagnostischer marker und therapeutisches ziel für eierstockkrebs
US20110009323A1 (en) * 2007-06-15 2011-01-13 Vasgene Therapeutics, Inc. Non-immunoglobulin antigen binding scaffolds for inhibiting angiogenesis and tumor growth
AU2008287427B2 (en) 2007-08-13 2014-10-09 Vasgene Therapeutics, Inc. Cancer treatment using humanized antibodies that bind to EphB4
US8357501B2 (en) 2007-11-29 2013-01-22 Molecular Health Gmbh Tissue protective erythropoietin receptor (NEPOR) and methods of use
AU2015204311B2 (en) * 2007-11-29 2017-06-08 Molecular Health Gmbh Novel tissue protective erythropoietin receptor (NEPOR) and methods of use
PL2492355T3 (pl) * 2007-11-29 2015-09-30 Molecular Health Gmbh Receptor erytropoetyny ochronny dla tkanki (nepor) i sposoby zastosowania

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989006692A1 (en) * 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
US5635177A (en) * 1992-01-22 1997-06-03 Genentech, Inc. Protein tyrosine kinase agonist antibodies
ATE293989T1 (de) * 1998-11-20 2005-05-15 Genentech Inc Verwendung von eph-rezeptor-antagonisten und agonisten zur behandlung von vaskulären krankheiten
US7442776B2 (en) * 1999-10-08 2008-10-28 Young David S F Cancerous disease modifying antibodies
WO2002026827A1 (en) 2000-09-29 2002-04-04 Novartis Ag Extracellular polypeptides of eph b receptors and ephrin b ligands and the corresponding nucleic acid molecules
KR100576674B1 (ko) * 2001-06-20 2006-05-10 제넨테크, 인크. 종양의 진단 및 치료를 위한 방법 및 이를 위한 조성물
EP1606305A4 (de) 2003-03-12 2009-06-24 Vasgene Therapeutics Inc Nukleinsäureverbindungen für die inhibierung von angiogenese und tumorwachstum

Also Published As

Publication number Publication date
CN1694902B (zh) 2012-10-10
ZA200502863B (en) 2006-06-28
US20060134118A1 (en) 2006-06-22
MXPA05002894A (es) 2005-10-05
KR20050072744A (ko) 2005-07-12
ES2355503T3 (es) 2011-03-28
NZ539203A (en) 2008-05-30
JP4799863B2 (ja) 2011-10-26
AU2002951409A0 (en) 2002-09-26
BR0314369A (pt) 2005-08-09
CA2499130A1 (en) 2004-03-25
JP2006517906A (ja) 2006-08-03
DE60334820D1 (de) 2010-12-16
WO2004024773A1 (en) 2004-03-25
US7722866B2 (en) 2010-05-25
EP1546205A4 (de) 2006-05-03
EP1546205A1 (de) 2005-06-29
EP1546205B1 (de) 2010-11-03
CN1694902A (zh) 2005-11-09

Similar Documents

Publication Publication Date Title
DE60334820D1 (de) Verfahren zur kontrolle von krebs
NO2017040I2 (no) Natalizumab, anti alfa-4 integrin humanisert monoklonalt antistoff - forlenget SPC
ATE473754T1 (de) Verfahren zur manipulation der zelldifferenzierung
ATE464908T1 (de) Verfahren zur behandlung von osteoarthritis mit anti-il-6 antikörpern
BRPI0613382A8 (pt) anticorpos isolados, anticorpo monoclonal, célula de hibridoma, método de identificação, método de inibição do crescimento de uma célula, método de tratamento terapêutico, método de determinação da presença de uma proteína, métodos de diagnósticos da presença de tumor
ATE509955T1 (de) Humanisierte kollagen-antikörper und damit verbundene verfahren
UA87804C2 (ru) Моноклональное антитело человека, которое специфически связывается с рецептором инсулиноподобного фактора роста і (igf-ir)
CO5580797A2 (es) Anticuerpos anti-cd33 y metodo para tratamiento de leucemia mieloide aguda utilizando los mismos
EA200401198A1 (ru) АНТИТЕЛА ПРОТИВ αvβ6
DE602005017781D1 (de) Rekonstituierter histon-methyltransferase-komplex und verfahren zur identifizierung von modulatoren dafür
NZ594466A (en) Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies
DK1325033T3 (da) Inhibering af komplement C5 aktivering til behandlingen og forebyggelsen af forsinket xenograf- eller akut vaskulær afstødning
DE602006013029D1 (de) Anti-egfr-antikörper
DE602004023965D1 (de) Anti-il-20-antikörper und bindungspartner und verfahren zur anwendung bei entzündungen
GEP20094829B (en) Fully human antibodies against human 4-1bb (cd137)
DK0724456T3 (da) CD40-Antistoffer
ATE485517T1 (de) Verfahren zur identifizierung von polypeptid- targets
DE3687884D1 (de) Monoklonale antikoerper und verfahren zum nachweis von pilzpathogenen.
ATE476989T1 (de) Humanisierter monoklonaler antikörper gegen von- willebrand faktor
EP1411962A4 (de) Behandlung von bauchspeicheldrüsenkrebs mit einem monoklonalen antikörper
DE60223688D1 (de) Verfahren zur behandlung von multiplem myelom
DE602004030041D1 (de) Verfahren und zusammensetzungen zur identifikation von rna-bindenden proteinen
DE69615843D1 (de) Il-8 antagonisten zur behandlung von asthma
ATE285418T1 (de) Humanisierter antikörper spezifisch für das oberflächenantigen pre-s1 von hbv und dessen präparation
DE602006021324D1 (de) Verfahren zur herstellung stabiler b-lymphozyten

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties